自2026年1月13日结算时起，铂、钯期货合约涨跌停板幅度调整为16%，交易保证金标准调整为18%。如遇上述涨跌停板幅度、交易保证金标准与现行执 行的涨跌停板幅度、交易保证金标准不同时，则按两者中幅度大、标准高的执行。 EIA短期能源展望报告1月13日发布 // 市场要闻 // 中国将公布12月进出口数据 1月14日周三中国将公布12月进出口数据。中金公司认为，过去几个月出口同比增速的波动，很大程度上可以归结于基数扰动，而12月基数较11月有所上 升，或使得12月出口同比增速较11月有所下降。预计12月出口同比增长3.0%，11月为5.9%；进口同比下降2.9%，11月为1.9%。 中国将公布2025年12月贸易帐 1月14日，中国将公布2025年12月贸易帐。根据海关总署及相关机构数据，2025年1-11月中国货物贸易进出口总值达41.21万亿元人民币，同比增长3.6%。 其中，出口24.46万亿元，同比增长6.2%；进口16.75万亿元，同比微增0.2%，贸易顺差达7.71万亿元（约1.076万亿美元），创历史首次突破万亿美元大 关，同比增长21.7%。 广期所：铂、钯期货合约涨跌停板幅度调整为16% 美 ...

近日，根据国家药品监督管理局药品审评中心（CDE）发布的公示信息，华东医药股份有限公司（以下 简称"公司"）控股子公司浙江道尔生物科技有限公司（以下简称"道尔生物"）自主研发的同类首创 （FIC）的靶向成纤维细胞生长因子21受体（Fibroblast growth factor 21 receptor，FGF21R），胰高血糖 素受体（Glucagon receptor，GCGR），和胰高血糖素样肽-1受体（Glucagon-like peptide-1 receptor， GLP-1R)的长效三靶点激动剂DR10624被纳入突破性治疗品种，拟定适应症为重度高甘油三酯血症 （severe hypertriglyceridemia，sHTG），现将有关详情公告如下： 一、该药物基本信息 药物名称：DR10624注射液 注册分类：治疗用生物制品1类 受理号：CXSB2300148 登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 二、该药物研发及注册情况 DR10624是道尔生物自主研发的全球首创的靶向FGF21R、 ...

Market News - China will release December import and export data on January 14, with exports expected to grow by 3.0% year-on-year, down from 5.9% in November, while imports are anticipated to decline by 2.9% [3] - The trade balance for December 2025 will also be published on January 14, with total goods trade from January to November 2025 reaching 41.21 trillion yuan, a year-on-year increase of 3.6% [3] Commodity Futures - The Shanghai Futures Exchange will adjust the price limit for platinum and palladium futures contracts to 16% starting from January 13, 2026, with the trading margin standard set at 18% [4] Energy Outlook - The U.S. Energy Information Administration (EIA) will release its Short-Term Energy Outlook report on January 13, maintaining the WTI crude oil price forecast for 2025 at slightly below $69 per barrel [5] U.S. Economic Data - The U.S. will release December CPI data on January 13, with core CPI expected to rebound significantly, predicted at 0.36% by Morgan Stanley and 0.38% by Bloomberg, both higher than the average of 0.08% in October and November [6] - Key economic indicators including October and November PPI and November retail sales will also be released, with expectations of moderate PPI growth and a 0.7% rebound in retail sales for November [6] Federal Reserve - The Federal Reserve will publish its latest Beige Book on January 14, indicating that government shutdowns and AI applications have weakened the job market, while rising tariffs and healthcare costs have increased business expenses [7] Earnings Season - The earnings season for Q4 2025 will commence this week, with major banks including JPMorgan, Citigroup, and Goldman Sachs set to report [8] Sector Events - The second China eVTOL Innovation Development Conference is scheduled for January 15-16, 2026, in Shanghai, focusing on the new commercial era of eVTOL [10] - The fourth Data Center Liquid Cooling & AI Chip Thermal Management Supply Chain Conference will be held on January 14-15, 2026, in Shenzhen [10] - China's first comprehensive law in the nuclear energy sector, the Atomic Energy Law, will take effect on January 15, 2026 [11] Individual Company News - Hangyu Technology announced on January 11 that it has repurchased 752,800 shares, with plans to sell them within six months [13] - Huadong Medicine's subsidiary has developed a breakthrough treatment for severe hypertriglyceridemia, which has been included in the list of breakthrough therapies by the National Medical Products Administration [13] - Jingfeng Mingyuan plans to acquire 100% of Sichuan Yichong Technology Co., with a key review meeting scheduled for January 16, 2026 [13] - TSMC has commenced research on its next-generation 1.4nm process, with risk trial production expected to start in 2027 [13] Lock-up Expiration - From January 12 to January 16, 2026, 23 companies will have lock-up shares released, totaling 2.434 billion shares with a market value of approximately 48.56 billion yuan [16] - The highest market value of lock-up shares released on January 12 is from Tianxin Pharmaceutical at 7.84 billion yuan [17] New Stock Calendar - Two new stocks are set to be issued this week, with a total issuance of approximately 34 million shares and expected fundraising of 1.909 billion yuan [19] Market Outlook - The current market enthusiasm is driven by concentrated inflows from previously cautious funds, with expectations for continued momentum in thematic and small-cap stocks until after the Two Sessions [22] - Guojin Securities suggests that the spring market is likely to perform well, with a focus on AI investments and the recovery of domestic manufacturing [23] - Everbright Securities anticipates sustained market heat but warns of potential cooling as the Lunar New Year approaches, recommending attention to sectors like electronics and power equipment [24]

证券代码：000963 证券简称：华东医药 公告编号：2026-001 华东医药股份有限公司 关于控股子公司产品纳入突破性治疗品种名单的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 近日，根据国家药品监督管理局药品审评中心（CDE）发布的公示信息，华东医药股份有限公司（以下 简称"公司"）控股子公司浙江道尔生物科技有限公司（以下简称"道尔生物"）自主研发的同类首创 （FIC）的靶向成纤维细胞生长因子21受体（Fibroblast growth factor 21 receptor，FGF21R），胰高血糖 素受体（Glucagon receptor，GCGR），和胰高血糖素样肽-1受体（Glucagon-like peptide-1 receptor， GLP-1R)的长效三靶点激动剂DR10624被纳入突破性治疗品种，拟定适应症为重度高甘油三酯血症 （severe hypertriglyceridemia，sHTG），现将有关详情公告如下： 一、该药物基本信息 药物名称：DR10624注射液 注册分类：治疗用生物制品1类 登录新浪财经APP 搜索【信 ...

今日晚间重要公告抢先看——嘉美包装股票将于1月12日复牌；德福科技宣布终止收购卢森堡铜箔100% 股权；中国有色矿业预计2026年综合铜产量约48.4万吨。 中国有色矿业：预计2026年综合铜产量约48.4万吨 中国有色矿业公告，谦比希东南矿体主、副井于2025年12月完成修复工作，修复效果符合预期，该矿山 已于2026年1月1日正式复产。公司预计2026年综合铜产量约48.4万吨，其中阴极铜约13.4万吨，粗铜╱ 阳极铜约35万吨(含铜产品代加工服务)。受谦比希铜冶炼和卢阿拉巴铜冶炼按计划停产检修影响，粗铜 ╱阳极铜产量将有所下降。全年预计自有矿产产铜约15.5万吨；生产硫酸约90万吨；生产液态二氧化硫 约10万吨；生产氢氧化钴含钴约600吨。 华东医药：子公司产品纳入突破性治疗品种名单 华东医药（000963）公告，控股子公司浙江道尔生物科技有限公司自主研发的DR10624注射液被纳入突 破性治疗品种，拟定适应症为重度高甘油三酯血症。DR10624是全球首创的靶向FGF21R、GCGR、 GLP-1R的长效三特异性激动剂，分别于2023年10月及2025年10月获得中国CDE以及美国FDA批准开展 针对s ...

Group 1: Dongshan Precision - Dongshan Precision reported a revenue of 27.071 billion yuan for the first three quarters, a year-on-year increase of 2.28% [1] - The net profit attributable to shareholders for the same period was 1.223 billion yuan, up 14.61% year-on-year [1] - In Q3, the company achieved a revenue of 10.115 billion yuan, a 2.82% increase year-on-year, but the net profit decreased by 8.19% to 465 million yuan [1] Group 2: Zhejiang Huayuan - Zhejiang Huayuan's revenue for the first three quarters reached 541 million yuan, reflecting an 18.64% year-on-year growth [1] - The net profit attributable to shareholders was 78.9528 million yuan, up 29.30% year-on-year [1] - In Q3, the revenue was 197 million yuan, a 16.72% increase, while the net profit grew by 6.05% to 20.5973 million yuan [1] Group 3: Yingboer - Yingboer reported a revenue of 2.358 billion yuan for the first three quarters, a significant increase of 46.70% year-on-year [2] - The net profit attributable to shareholders surged by 191.18% to 149 million yuan [2] - In Q3, the revenue was 989 million yuan, up 69.40%, and the net profit skyrocketed by 580.62% to 112 million yuan [2] Group 4: Yichang Technology - Yichang Technology's revenue for the first three quarters was 2.106 billion yuan, a 14.30% increase year-on-year [3] - The net profit attributable to shareholders fell by 46.84% to 38.0785 million yuan [3] - In Q3, the revenue was 715 million yuan, up 11.13%, while the net profit increased by 193.37% to 3.6538 million yuan [3] Group 5: Stanley - Stanley reported a revenue of 9.290 billion yuan for the first three quarters, a year-on-year increase of 17.91% [4] - The net profit attributable to shareholders was 815 million yuan, reflecting a 22.71% growth [4] - In Q3, the revenue reached 2.899 billion yuan, up 31.41%, and the net profit increased by 35.36% to 208 million yuan [4] Group 6: Wen's Shares - Wen's Shares reported a revenue of 75.788 billion yuan for the first three quarters, a slight decline of 0.03% year-on-year [6] - The net profit attributable to shareholders decreased by 18.29% to 5.256 billion yuan [6] - In Q3, the revenue was 25.937 billion yuan, down 9.76%, and the net profit fell sharply by 65.02% to 1.781 billion yuan [6] Group 7: China XD Electric - China XD Electric achieved a revenue of 16.959 billion yuan for the first three quarters, a year-on-year increase of 11.85% [7] - The net profit attributable to shareholders was 939 million yuan, up 19.29% [7] - In Q3, the revenue was 5.658 billion yuan, reflecting a 15.98% increase, while the net profit grew by 1.78% to 340 million yuan [7] Group 8: Huayi Group - Huayi Group reported a revenue of 35.708 billion yuan for the first three quarters, a decline of 5.02% year-on-year [8] - The net profit attributable to shareholders fell by 42.68% to 395 million yuan [8] - In Q3, the revenue was 11.708 billion yuan, down 9.75%, and the company reported a net loss of 92.7736 million yuan [8] Group 9: Zhiwei Intelligent - Zhiwei Intelligent's revenue for the first three quarters was 2.973 billion yuan, a 6.89% increase year-on-year [9] - The net profit attributable to shareholders rose by 59.3% to 131 million yuan [9] - In Q3, the revenue was 1.026 billion yuan, up 6.08%, and the net profit increased by 13.67% to 29.2356 million yuan [9] Group 10: Shiyi Da - Shiyi Da reported a revenue of 485 million yuan for the first three quarters, reflecting a 7.26% year-on-year growth [10] - The net profit attributable to shareholders was 30.3088 million yuan, up 12.37% [10] - In Q3, the revenue reached 176 million yuan, a 29.81% increase, while the net profit surged by 471.34% to 14.8444 million yuan [10] Group 11: Poly Developments - Poly Developments reported a revenue of 173.722 billion yuan for the first three quarters, a decline of 4.95% year-on-year [13] - The net profit attributable to shareholders fell by 75.31% to 1.929 billion yuan [13] - In Q3, the revenue was 56.865 billion yuan, up 30.65%, but the company reported a net loss of 782 million yuan [13] Group 12: Huadong Medicine - Huadong Medicine's subsidiary received FDA approval for clinical trials of DR10624 injection targeting severe hypertriglyceridemia [14] - DR10624 is a globally first-of-its-kind long-acting tri-specific agonist [14] Group 13: Lihua Microelectronics - Lihua Microelectronics announced a plan to reduce its shareholding by up to 3% due to operational needs [16] - The reduction will occur through centralized bidding and block trading from November 13, 2025, to February 12, 2026 [16] Group 14: Greebo - Greebo secured a significant order worth 60 million USD from a leading US home improvement retailer for lithium outdoor power equipment [17] - The order is expected to be delivered by the end of January 2026 [17] Group 15: ST Jingfeng - ST Jingfeng's stock will be subject to delisting risk warning due to the court's acceptance of creditor restructuring application [20] - The stock will resume trading on October 23, 2025, under the name "*ST Jingfeng" [20] Group 16: Yinxin Development - Yinxin Development plans to acquire 81.81% of Guangdong Changxing Semiconductor Technology Co., Ltd. [22] - The acquisition is expected to result in Yinxin Development gaining control over Changxing Semiconductor [22]

Core Viewpoint - The announcement from East China Pharmaceutical indicates that its subsidiary, Zhejiang Daer Biotechnology Co., Ltd., has received FDA approval for the clinical trial application of the DR10624 injection, targeting severe hypertriglyceridemia [1] Group 1: Clinical Trial Approval - The DR10624 injection has been approved by the FDA to conduct clinical trials in the United States for the indication of severe hypertriglyceridemia [1] - The drug has successfully completed Phase II clinical studies for severe hypertriglyceridemia, yielding positive topline results post-blinding [1] Group 2: Clinical Research Results - At the EASL Congress 2025, Daer Biotechnology reported that the Phase Ib/IIa clinical study of DR10624 for obesity combined with hypertriglyceridemia showed a maximum liver fat reduction of 89% and a relative triglyceride reduction exceeding 70% from baseline [1] - A Phase II clinical study for DR10624, targeting metabolic-associated fatty liver disease with high risk of liver fibrosis and alcohol-related fatty liver disease, is set to complete its first subject enrollment by April 2025 [1] Group 3: Additional Approvals - The clinical trial application for DR10624 targeting weight management in type 2 diabetes and overweight or obese populations has also been approved in China [1] - Daer Biotechnology submitted the clinical trial application for DR10624 to the FDA in September 2025 and has recently received approval [1]

Core Viewpoint - Huadong Medicine (000963.SZ) announced that its subsidiary, Zhejiang Daer Biotechnology Co., Ltd. (referred to as "Daer Bio"), has received approval from the U.S. Food and Drug Administration (FDA) for the clinical trial application of the drug DR10624, which targets severe hypertriglyceridemia (SHTG) [1] Group 1 - Daer Bio's DR10624 is a first-in-class long-acting tri-specific agonist targeting fibroblast growth factor 21 receptor (FGF21R), glucagon receptor (GCGR), and glucagon-like peptide-1 receptor (GLP-1R) [1] - The drug is designed with a chimeric peptide segment targeting GLP-1R/GCGR fused with an engineered IgG1 Fc, incorporating a recombinant FGF21 mutant at the C-terminus of Fc [1]

Core Viewpoint - The announcement indicates that East China Pharmaceutical's subsidiary, Zhejiang Daor Biotechnology Co., Ltd., has received FDA approval for clinical trials of the drug DR10624 in the United States [2] Group 1 - East China Pharmaceutical's subsidiary, Daor Biotechnology, has successfully submitted a clinical trial application for the drug DR10624 [2] - The FDA's approval allows Daor Biotechnology to conduct clinical trials in the U.S. market [2]

Core Viewpoint - Huadong Medicine's subsidiary, Zhejiang Daer Biotechnology Co., Ltd., has received FDA approval for clinical trials of its drug DR10624 in the U.S., targeting severe hypertriglyceridemia [1] Company Summary - Huadong Medicine announced that its subsidiary, Zhejiang Daer Biotechnology, has successfully obtained FDA approval for the clinical trial application of DR10624 injection [1] - The approved indication for DR10624 is severe hypertriglyceridemia, a condition characterized by high levels of triglycerides in the blood [1] Industry Summary - The approval from the FDA allows for the commencement of clinical trials in the U.S., which is a significant step for the company in the biopharmaceutical sector [1]